Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
Revolutionizing Pediatric Care: Approval of Malaria Medicine for Newborns
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
EMA 2024 Report Highlights: Innovations in Medicine Approval and Regulatory A...
NICE Approves Transformative Multiple Myeloma Treatment
EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Co...
Pfizer Conference Insights: Analyzing Bourla’s Strategic Vision Amid Po...
Revitalizing Innovation: The Impact of UK Medicine Payment Rates
Blinatumomab Benefit Assessment for ALL and Health Economics
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global He...
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...